Eoy1

TRANSFORMING LIVES

100% of proceeds benefit families living with MS

DONATE

Upcoming Programs & Events

07 Nov
JUMPSTART Program: Healthy Mind; Healthy Body

  Saturday 11/7 @ 1pm ET

  Online

10 Nov
Integrative Nutrition

  Tuesday 11/10 @ 8pm ET

  Online


TOGETHER, TRANSFORMING LIVES

Can Do MS delivers health and wellness education programs to help families living with MS thrive.

RECENT NEWS


This September, show the world how you #ThriveWithMS to inspire others and spread awareness of multiple sclerosis

Can Do Multiple Sclerosis, a non-profit that delivers health and wellness education programs for families with MS, launched their annual, online campaign today that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.

+
Color Street Foundation pledges $100,000 to support MS awareness

For the month of August, the Color Street Foundation is pledging $100,000 to support awareness, research, and direct support programs for those who live with MS. 

+
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS

ROCKLAND, Mass., May 27, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today the U.S. Food and Drug Administration (FDA) has approved the inclusion of new safety data on pregnancy and breastfeeding in the prescribing information for Rebif® (interferon beta-1a), in accordance with the FDA's Pregnancy and Lactation Labeling Rule (PLLR). 

+
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA®

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that ZEPOSIA® (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, is now commercially available in the U.S. ZEPOSIA was approved by the U.S. Food and Drug Administration (FDA) on March 25, 2020.

+